218 related articles for article (PubMed ID: 29968534)
21. Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.
Ruiz-Argüello MB; Maguregui A; Ruiz Del Agua A; Pascual-Salcedo D; Martínez-Feito A; Jurado T; Plasencia C; Balsa A; Llinares-Tello F; Rosas J; Torres N; Martínez A; Nagore D
Ann Rheum Dis; 2016 Sep; 75(9):1693-6. PubMed ID: 26965981
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of Infliximab-Treated inflammatory bowel disease patients undergoing therapeutic drug monitoring with two different assays.
Al-Bawardy B; Jenkins SM; Snyder MR; Frinack JL; Ladwig PM; Loftus EV; Willrich MAV
Clin Biochem; 2023 Sep; 119():110618. PubMed ID: 37507083
[TBL] [Abstract][Full Text] [Related]
23. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
[TBL] [Abstract][Full Text] [Related]
24. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
[TBL] [Abstract][Full Text] [Related]
25. A review of six methods for monitoring infliximab concentrations and antibodies to infliximab
.
Cao F; Cao H; Cao X
Int J Clin Pharmacol Ther; 2017 Jul; 55(7):571-580. PubMed ID: 28513424
[TBL] [Abstract][Full Text] [Related]
26. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays.
Afonso J; Lopes S; Gonçalves R; Caldeira P; Lago P; Tavares de Sousa H; Ramos J; Gonçalves AR; Ministro P; Rosa I; Vieira AI; Dias CC; Magro F;
Aliment Pharmacol Ther; 2016 Oct; 44(7):684-92. PubMed ID: 27507790
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Bevacizumab Quantification Results in Plasma of Non-small Cell Lung Cancer Patients Using Bioanalytical Techniques Between LC-MS/MS, ELISA, and Microfluidic-based Immunoassay.
Iwamoto N; Takanashi M; Shimada T; Sasaki J; Hamada A
AAPS J; 2019 Aug; 21(6):101. PubMed ID: 31432293
[TBL] [Abstract][Full Text] [Related]
28. Quantitation of infliximab using clonotypic peptides and selective reaction monitoring by LC-MS/MS.
Willrich MA; Murray DL; Barnidge DR; Ladwig PM; Snyder MR
Int Immunopharmacol; 2015 Sep; 28(1):513-20. PubMed ID: 26210595
[TBL] [Abstract][Full Text] [Related]
29. Infliximab Biosimilar (Remsima™) in Therapy of Inflammatory Bowel Diseases Patients: Experience from One Tertiary Inflammatory Bowel Diseases Centre.
Kolar M; Duricova D; Bortlik M; Hruba V; Machkova N; Mitrova K; Malickova K; Lukas M; Lukas M
Dig Dis; 2017; 35(1-2):91-100. PubMed ID: 28147356
[TBL] [Abstract][Full Text] [Related]
30. SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT.
Teixeira FV; Sassaki LY; Saad-Hossne R; Baima JP; Magro DO; Coy CSR; Kotze PG
Arq Gastroenterol; 2018; 55(2):192-197. PubMed ID: 30043873
[TBL] [Abstract][Full Text] [Related]
31. Bioanalysis of therapeutic monoclonal antibody by peptide adsorption-controlled LC-MS.
Hashii N; Tousaka Y; Arai K; Enoki Y; Fukuda S; Goda R; Inoue N; Kawabata M; Murata K; Nakatsuji M; Okuzono T; Shigeyama T; Tachiki H; Yamaguchi T; Yamane S; Yamaoka M; Saito Y; Ishii-Watabe A
Bioanalysis; 2021 Feb; 13(4):265-276. PubMed ID: 33543661
[No Abstract] [Full Text] [Related]
32. A rapid and universal liquid chromatograph-mass spectrometry-based platform, refmAb-Q nSMOL, for monitoring monoclonal antibody therapeutics.
Iwamoto N; Koguchi Y; Yokoyama K; Hamada A; Yonezawa A; Piening BD; Tran E; Fox BA; Redmond WL; Shimada T
Analyst; 2022 Sep; 147(19):4275-4284. PubMed ID: 35997223
[TBL] [Abstract][Full Text] [Related]
33. The Utility of Infliximab Therapeutic Drug Monitoring among Patients with Inflammatory Bowel Disease and Concerns for Loss of Response: A Retrospective Analysis of a Real-World Experience.
Mitchell RA; Shuster C; Shahidi N; Galorport C; DeMarco ML; Rosenfeld G; Enns RA; Bressler B
Can J Gastroenterol Hepatol; 2016; 2016():5203898. PubMed ID: 27957480
[No Abstract] [Full Text] [Related]
34. Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels.
Ogrič M; Žigon P; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S; Praprotnik S
Immunol Res; 2018 Dec; 66(6):726-736. PubMed ID: 30569379
[TBL] [Abstract][Full Text] [Related]
35. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
36. An automated mass spectrometric blood test for therapeutic drug monitoring of infliximab.
van der Gugten JG; Bressler B; DeMarco ML
Clin Mass Spectrom; 2019 Apr; 12():16-22. PubMed ID: 34841075
[TBL] [Abstract][Full Text] [Related]
37. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
[TBL] [Abstract][Full Text] [Related]
38. LC-MS/MS approach for quantification of therapeutic proteins in plasma using a protein internal standard and 2D-solid-phase extraction cleanup.
Yang Z; Hayes M; Fang X; Daley MP; Ettenberg S; Tse FL
Anal Chem; 2007 Dec; 79(24):9294-301. PubMed ID: 17999465
[TBL] [Abstract][Full Text] [Related]
39. Viability of a Serum Infliximab Concentration-Detecting Reagent as a Qualitative Assay for an Infliximab Biosimilar.
Inagaki T; Isesaki T; Kawana K; Funakoshi R
Biol Pharm Bull; 2021; 44(9):1272-1279. PubMed ID: 34471055
[TBL] [Abstract][Full Text] [Related]
40. Analysis of Tryptic Peptides from Therapeutic Monoclonal Antibodies Using LC-MS/MS.
Willrich MAV
Methods Mol Biol; 2019; 1872():85-99. PubMed ID: 30350282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
